Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469209 · ClinicalTrials.gov registry record · Phase 1
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
A Phase 1 study of Myeloma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00469209: Completed Phase 1 study of Myeloma, sponsored by M.D. Anderson Cancer Center.
NCT00469209 is a Phase 1 study of Myeloma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00469209, a Phase 1 study of Myeloma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Primary Objectives: 1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma 2. To evaluate the efficacy of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma 3. To determine the effects of bortezomib on melphalan pharmacokinetics
Primary Outcome
Number of participants with CR at Day 180 who had maintained CR for at minimum of 4 weeks, and who had: No monoclonal protein in urine/serum when analyzed by immunofixation electrophoresis; bone marrow normal by morphological examination with \<5% plasma cells, \<1% aneuploid light chain restricted population by flow cytometry for DNA/cIg; and, while healing of bony lesion is not required, no new lytic lesion should appear. Further compression fracture of spine not considered progressive disease
Conditions Studied
Interventions
- DRUG Melphalan
- DRUG Trisenox (Arsenic Trioxide)
- DRUG Velcade (Bortezomib)
- DRUG Vitamin C (Ascorbic Acid)
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-06 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
What the finished NCT00469209 record still lists
NCT00469209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 98-participant average among 29 other Myeloma trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT00469209 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00469209 about?
NCT00469209 is a clinical study titled "Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients". Primary Objectives: 1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma 2. To evaluate the efficacy of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melp...
What is the current status of trial NCT00469209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2006-06. Estimated completion is 2008-12.
What conditions does trial NCT00469209 study?
This clinical trial studies the following conditions: Myeloma.
What interventions are being tested in trial NCT00469209?
The interventions under investigation include: Melphalan (DRUG), Trisenox (Arsenic Trioxide) (DRUG), Velcade (Bortezomib) (DRUG), Vitamin C (Ascorbic Acid) (DRUG).
Who is sponsoring clinical trial NCT00469209?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00469209 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00469209's enrollment target sits among peer trials
60 11th of 29 higher than 17 of 29 other Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 1
-
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
RECRUITING · Phase 1
-
Pilot Imaging Study of Leukemia
RECRUITING · Phase 1
-
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia